Table 3.

All SARI admissions and Influenza‐associated SARI admissions during influenza epidemic weeks

	Dominant influenza strains	Influenza vaccine match a	% of target groups vaccinated c	Epidemic duration (weeks)	Observed crude SARI b incidence (during influenza epidemics)	Influenza‐associated SARI b incidence (during influenza epidemics)	Influenza‐associated SARI b proportion (during influenza epidemics)
2007/2008	A(H1N1) dominance followed by B dominance	mismatch	74%	8	929	58	6%
2008/2009	A(H3N2) dominance	match	72%	5	731	88	12%
2009/2010	A(H1N1)pdm09 dominance	mismatch	70%	8	806	178	22%
2010/2011	A(H1N1)pdm09 dominance followed by B dominance	match	69%	7	890	153	17%
2011/2012	A(H3N2) dominance	mismatch	66%	0	NA	NA	NA
2012/2013	Mixed A(H1N1)pdm09 and A(H3N2) dominance followed by B dominance	mismatch	62%	16	1996	418	21%
2013/2014	Mixed dominance with slightly more A(H3N2) than A(H1N1)pdm09	mismatch	60%	6	544	0	0%
2014/2015	A(H3N2) dominance followed by B dominance	mismatch	57%	20	2366	404	17%
2015/2016	A(H1N1)pdm09 dominance followed by B dominance	match	56%	12	1693	455	27%
2007/2016	Yearly average			9	1244	219	18%

^aVaccine match with the dominant influenza strain(s).

^bStandardized to the number of medical ICU admissions in season 2015.

^cIndividuals aged 60 years or older and individuals with comorbidity who have an increased risk of complications or death due to influenza infection, % as reported previously (Ref 23, 24).